ArticleClinical research in cardiology : official journal of the German Cardiac Society2009
Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Paclitaxel-Coated versus Uncoated Balloon for Femoropopliteal In-Stent Restenosis: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2022Pooled it
- Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis: An Updated Systematic Review and Meta-Analysis.Chinese medical journal · 2018Pooled it
- Pooled it
- Trial
- Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentre German Cypher Stent Registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2010Trial
- Beyond the Stent ("Leave-Nothing-Behind") Drug-Coated Balloons in Acute Coronary Syndrome: A Narrative Review.Journal of clinical medicine · 2026Review
- Safety and Efficacy of an Innovative Everolimus-Coated Balloon in a Swine Coronary Artery Model.Life (Basel, Switzerland) · 2023Article
- Drug Coated Balloon in the Treatment of De Novo Coronary Artery Disease: A Narrative Review.Journal of clinical medicine · 2023Review
- Choosing the right treatment for the right lesion, Part II: a narrative review of drug-coated balloon angioplasty and its evolving role in dialysis access maintenance.Cardiovascular diagnosis and therapy · 2023Review
- Drug-coated Balloons for Small Coronary Vessel Interventions: A Literature Review.Interventional cardiology (London, England) · 2019Review
- Drug Distribution and Basic Pharmacology of Paclitaxel/Resveratrol-Coated Balloon Catheters.Cardiovascular and interventional radiology · 2018Article
- Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2.Clinical cardiology · 2018Article
- Drug-coated Balloon-only Angioplasty for Native Coronary Disease Instead of Stents.Interventional cardiology (London, England) · 2016Article
- Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease.Vascular health and risk management · 2016Review
- Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis.Bio-medical materials and engineering · 2015Article
- Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention.Biomacromolecules · 2014Review
- Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis.Clinical research in cardiology : official journal of the German Cardiac Society · 2014Article
- Drug-coated balloon therapy in coronary and peripheral artery disease.Nature reviews. Cardiology · 2014Review
- Drug-coated balloons for coronary and peripheral interventional procedures.Current cardiology reports · 2012Review
- Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-eluting balloon (DEB) catheters coated with paclitaxel in a water-soluble matrix have shown beneficial effects in the treatment and prevention of restenosis in the porcine coronary overstretch model and in clinical trials. Adherence of paclitaxel, same dose, on another recently introduced coated percutaneous coronary intervention (PCI) catheter (DIOR) is mediated by a roughened balloon surface. Only scarce experimental and clinical data has been published on the new coating method. The aim of the present study was to compare the safety and efficacy of the two coatings in the porcine model. METHODS AND
resultsTwenty-eight stainless steel stents were implanted in the left anterior descending and circumflex coronary arteries of 14 domestic pigs using either matrix-coated (n = 8), roughened DEB (n = 9), or uncoated PCI catheters, which served as control (n = 11). After 28 days, quantitative angiography and histomorphometry of the stented arteries were performed. Matrix-coated DEB led to a highly significant (P < 0.01) reduction of all parameters indicating neointimal proliferation compared to both, uncoated control and the roughened DEB; late lumen loss in-segment was 0.4 +/- 0.2, 1.9 +/- 0.5, and 1.4 +/- 0.5 mm, respectively. In contrast, the roughened DEB failed to produce statistically significant effects on angiographic measures of stenosis or morphometric parameters such as maximal neointimal thickness and luminal area, except for neointimal area (5.7 +/- 1.5 mm(2) in the control group, 4.1 +/- 1.7 mm(2) roughened DEB, P < 0.05 vs. control, and 2.5 +/- 0.8 mm(2) matrix-coated DEB, P < 0.01 vs. control).
conclusionInhibition of neointimal proliferation in the porcine coronary overstretch model by paclitaxel depends critically on the coating method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.